Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Genmab A/S

Genmab (Otc) ($GMAB) announced an update on their ongoing clinical study. Study Overview: Genmab is conducting a Phase 3 study titled A Randomized,...

Genmab’s New Phase 3 Study: A Potential Game-Changer in Ovarian Cancer Treatment

Amid market volatility, technical analysis can help investors pinpoint promising stock opportunities. Using TipRanks’ Technical Analysis Screener, ...

UAL, SNDK, GMAB: 3 Stocks Technical Analysis Say Are Strong Buys

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Genmab (GMAB – Research Report), Omnicell (OMCL – Re...

Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Omnicell (OMCL) and Syndax Pharmaceuticals (SNDX)

In a report released today, Xian Deng from UBS maintained a Buy rating on Genmab A/S, with a price target of DKK2,700.00. Deng covers the Healthcar...

UBS Sticks to Their Buy Rating for Genmab A/S (0MGB)

In a report released on November 25, Sachin Jain from Bank of America Securities maintained a Buy rating on Genmab A/S, with a price target of DKK2...

Bank of America Securities Keeps Their Buy Rating on Genmab A/S (0MGB)

Genmab ( ($GMAB) ) has provided an update. On November 20, 2025, Genmab A/S announced the grant of 6,933 restricted stock units and 7,377 warrants ...

Genmab Grants Stock Units and Warrants to Employees

Genmab ( ($GMAB) ) just unveiled an update. On November 19, 2025, Genmab A/S announced transactions involving shares and linked securities conducte...

Genmab A/S Discloses Managerial Share Transactions

Genmab ( ($GMAB) ) has provided an announcement. Genmab A/S has updated its Articles of Association, authorizing the Board of Directors to increase...

Genmab A/S Updates Articles of Association to Enhance Capital Flexibility

The latest announcement is out from Genmab ( ($GMAB) ). On November 18, 2025, Genmab A/S announced a capital increase of 32,059 shares following th...

Genmab Announces Capital Increase Following Employee Warrant Exercise

Genmab ( ($GMAB) ) just unveiled an update. On November 18, 2025, Genmab A/S announced that the U.S. FDA approved EPKINLY® (epcoritamab-bysp) in co...

Genmab’s EPKINLY® Combination Therapy Gains FDA Approval for Follicular Lymphoma

In a report released on November 14, Jon Berggren from Kepler Capital maintained a Hold rating on Genmab A/S, with a price target of DKK2,100.00. T...

Market Cap	$20.47B	P/E Ratio	16.57
52W High	$33.65	52W Low	$17.24
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	0.0%	52W Position	85.7%
Overall Score	61	Value Score	60
Quality Score	42	Technical Score	83

EPS Current Est	$1.89	EPS Next Est	$1.66
EPS Growth Est	-12.2%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GMAB	$31.31	-3.07%	1.93M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GMAB	$31.31	-3.1%	1.93M
3
4
5
6

GMAB

GMAB

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Genmab A/S Data in Excel

Get Genmab A/S Data in Excel